Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

BACKGROUND: A randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy. METHODS: Multicentre, phase II study with 1:1 randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Jonathan E., Hahn, Noah M., Regan, Meredith M., Werner, Lillian, Alva, Ajjai, George, Saby, Picus, Joel, Alter, Robert, Balar, Arjun, Hoffman-Censits, Jean, Grivas, Petros, Lauer, Richard, Guancial, Elizabeth A., Hoimes, Christopher, Sonpavde, Guru, Albany, Constantine, Stein, Mark N., Breen, Tim, Jacobs, Cindy, Anderson, Kirsten, Bellmunt, Joaquim, Lalani, Aly-Khan A., Pal, Sumanta, Choueiri, Toni K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988804/
https://www.ncbi.nlm.nih.gov/pubmed/29765151
http://dx.doi.org/10.1038/s41416-018-0087-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988804/
https://www.ncbi.nlm.nih.gov/pubmed/29765151
http://dx.doi.org/10.1038/s41416-018-0087-9

Ejemplares similares